Zimmer Biomet Holdings, Inc.

ZBH Healthcare Medical Devices

Zimmer Biomet Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.2 billion, up 7.20% from fiscal 2024. In the quarter to June 2026, revenue grew 4.80%, EPS grew 33.8%, free cash flow grew 13.1% and total debt fell 1.23%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for five.

95.06 0.68 +0.72%
Market cap
$18.0B
P/E
23.0×
Fwd P/E
17.7×
Dividend yield
1.01%
F-score
6/9
Altman Z
2.38
Beneish M
−2.59
Dividend safety
72/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

6.40% 5.60% 6.07% 6.41%
Piotroski F-Score
6 6 6 6
ROA
3.56% 3.17% 3.39% 3.53%
ROIC
4.25% 3.50% 3.74% 3.82%
Return on Tangible Assets
14.31% 14.87% 17.66% 18.67%
Average Days of Receivables
72.82 75.58 75.03 75.91
Free Cash Flow per Share
5.11 5.44 5.17 5.39
Free Cash Flow
1,011.30 1,077.30 1,008.10 1,036.50
Capital Expenditures
(674.70) (619.80) (665.60) (706.80)
Other line items
Cash ROIC
4.56% 5.18% 4.90% 5.05%
Accounts Receivable Turnover
5.20 5.17 5.16 5.03
Accounts Payable Turnover
7.18 10.02 7.61 7.31
Inventory Turnover
0.94 1.10 1.12 1.09
Average Days of Payables
50.30 44.35 52.31 50.18
Days of Inventory on Hand
396.22 334.66 325.42 323.27
Tax Rate
(0.21) (0.15) (0.16) (0.14)
Research and Development Expense of Revenue
5.60% 5.57% 5.37% 5.20%
Selling, General and Administrative Expense of Revenue
39.09% 39.57% 39.82% 40.34%
Share Based Compensation of Revenue
1.09% 1.10% 1.13% 1.15%
Interest Coverage
4.71 3.75 3.99 4.17
Operating CF/Net income
2.09 2.41 2.20 2.16
Depreciation/Fixed assets
0.49 0.50 0.50 0.50
Capex/Depreciation
(0.63) (0.57) (0.60) (0.64)
Revenue per Share
40.44 41.57 43.12 44.27
Operating CF per Share
8.51 8.57 8.58 9.07
Capex per Share
(3.41) (3.13) (3.41) (3.68)
Capex to Sales
0.08 0.08 0.08 0.08

Fold the line items

Columns are period end dates